Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661802 | 0.98 | GAA (0.40) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL1578848 | 0.96 | GAA (0.41) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL29712098 | 0.87 | POLB (0.32) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7770339 | 0.85 | POLB (0.33) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL29712141 | 0.85 | POLB (0.33) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL30187480 | 0.80 | — | — | |
| SCHEMBL14992914 | 0.74 | — | — | |
| SCHEMBL28793536 | 0.73 | POLB (0.32) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 | |
| SCHEMBL27653742 | 0.70 | HSP90AA1 (0.31) | HSP90AA1MAPK1SMN1; SMN2KDM4ETHRB | |
| SCHEMBL29355518 | 0.68 | GAA (0.36) | GAAPOLBHSP90AA1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114585637-A | MASP inhibiting compounds and uses thereof | 拜耳公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-11261206-B2 | Olefin metathesis catalysts | UMICORE AG & CO. KG | 2022-03-01 | — | — | US | disclosed |
| US-20210155648-A1 | OLEFIN METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2021-05-27 | — | — | US | disclosed |
| EP-3500557-A1 | OLEFIN METATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018035319-A1 | OLEFIN METATHESIS CATALYSTS | MATERIA, INC. (US) | 2018-02-22 | — | — | WO | disclosed |
| CN-103403010-A | inhibitors of POLO-like kinases | ELAN PHARM INC | 2013-11-20 | — | — | CN | disclosed |
| CN-101090902-B | Cgrp receptor antagonists | MERCK SHARP & DOHME | 2013-05-29 | — | — | CN | disclosed |
| CN-101115735-B | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI | 2013-01-09 | — | — | CN | disclosed |
| WO-2009009158-A2 | METATHETIC PRODUCTION OF FUNCTIONALIZED POLYMERS | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| CN-101309894-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
| CN-101238106-A | Fluoro substituted 2-oxo azepan derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-06 | — | — | CN | disclosed |
| CN-101124217-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2008-02-13 | — | — | CN | disclosed |
| CN-101115735-A | Glucagon receptor antagonists, preparation and therapeutic uses | LILLY CO ELI (US) | 2008-01-30 | — | — | CN | disclosed |
| CN-101103008-A | Macrocyclic compounds useful as bace inhibitors | NOVARTIS AG (CH) | 2008-01-09 | — | — | CN | disclosed |
| CN-101090902-A | Cgrp receptor antagonists | MERCK & CO INC (US) | 2007-12-19 | — | — | CN | disclosed |
| CN-101068595-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2007-11-07 | — | — | CN | disclosed |
| CN-1863754-A | Process for the synthesis of unsaturated alcohols | DOW GLOBAL TECHNOLOGIES INC (US) | 2006-11-15 | — | — | CN | disclosed |
| CN-1802369-A | CGRP receptor antagonists | MERCK & CO INC (US) | 2006-07-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261206-B2 | Olefin metathesis catalysts | MOGAT2, SQLE, FDFT1 | GAA 3476/4885POLB 695/4885HSP90AA1 4514/4885 |
| US-20210155648-A1 | OLEFIN METATHESIS CATALYSTS | MOGAT2, SQLE, FDFT1 | GAA 3476/4885POLB 695/4885HSP90AA1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.